Cargando…
Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis
AS is the prototypical member of the family of spondyloarthropathies, and is characterized by seronegativity, axial predominance and new bone formation, which underlie symptoms of inflammatory back pain, enthesopathy and extra-articular manifestations, including anterior uveitis, psoriasis and colit...
Autores principales: | Bergman, Martin, Lundholm, Amy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850804/ https://www.ncbi.nlm.nih.gov/pubmed/28977661 http://dx.doi.org/10.1093/rheumatology/kex292 |
Ejemplares similares
-
Management of ankylosing spondylitis with infliximab
por: Toussirot, Éric, et al.
Publicado: (2009) -
Advances in managing ankylosing spondylitis
por: Daikh, David I., et al.
Publicado: (2014) -
Update on the treatment of ankylosing spondylitis
por: Maksymowych, Walter P
Publicado: (2007) -
Infliximab in the treatment of ankylosing spondylitis
por: Grainger, Rebecca, et al.
Publicado: (2007) -
Ankylosing Spondylitis
por: Ebrahimiadib, Nazanin, et al.
Publicado: (2021)